Table 3.
Characteristics and drug status of BCMA-targeting antibody drug conjugates.
| Agent | Cytotoxic Conjugate | Trial Phase | Drug Status/Published Results | NCT Number | References |
|---|---|---|---|---|---|
| Belantamab mafodotin (GSK2857916) | Monomethyl auristatin F (MMAF) | 2, 3 | First-in-class approval 2020; several studies with different drug combinations ongoing | NCT02064387 | [73] |
| MEDI2228 | Pyrrolobenzodiazepine (PBD) | 1 | Early phase 1 results published | NCT03489525 | [74] |
| HDP-101 | Amanitin | 1/2 | Phase 1 not yet recruiting | NCT04879043 | [75] |
| AMG-224 | Mertansine (DM1) | 1 | Early phase 1 results published; deprioritized in favor of the development of bispecific antibody constructs by the company | NCT02561962 | [76] |
| CC99712 | Undisclosed | 1 | Recruiting, no results available | NCT04036461 |